Drug Trial Radar · NCT05991349
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Mar 12, 2024
Primary completion
Nov 30, 2024
Study completion May 31, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2 multicenter, first-in-human study of IBI129. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI129, plan to enroll 22\~180 subjects, and a phase 2 to explore efficacy, safety and tolerability of IBI129 at RP2D in specified types of solid tumor. Approximately 182 evaluable subjects will be enrolled for phase 2
Conditions
- Solid Tumor
Interventions
IBI129Drug
Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse eventsTime frame: 24 months
- Number of subjects with clinically significant changes in physical examination resultsTime frame: 24 months
- Number of subjects with clinically significant changes in vital signsTime frame: 24 months
- MTD or RP2D of IBI129Time frame: 12 months
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
St George private Hospital
Kogarah, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Hubei Cancer Hospital
Wuhan, Hubei, China
The First Hospital of Jilin University
Changchun, Jilin, China
Shandong Cancer Hospital
Jinan, Shandong, China
Tianjin Medical university cancer institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.